Wockhardt’s novel antibiotic Zaynich eyes $9 billion global market
Mumbai-based pharma major Wockhardt, which is all set to launch its new class of antibiotic Zaynich targeted at treating complicated gram-negative infections in India this year, estimates that the drug…
Biocon Q4 net profit surges 153%, biosimilars, generics drive growth
Biocon, India’s leading biopharmaceutical company, reported a 153 percent year-on-year (YoY) jump in net profit for the fourth quarter of FY25, led by strong performances in its biosimilars and generics…
Biocon Bets Fired On Biosimilar For Revenue Growth
Searing growth in its biosimilar business is expected to help see Biocon cross $1 billion in revenue this fiscal. Biosimilars, or biologics, are biological drugs that are developed to be…